The	the	DT	O
predominant	predominant	JJ	O
pathophysiological	pathophysiological	JJ	O
factor	factor	NN	O
of	of	IN	O
type	type	NN	O
2	2	CD	O
diabetes	diabetes	NN	O
is	be	VBZ	O
insulin	insulin	NN	O
resistance	resistance	NN	B
.	.	.	O

Though	though	IN	O
many	many	JJ	O
anti	anti	JJ	O
-	-	JJ	O
T2D	t2d	JJ	O
drugs	drug	NNS	O
have	have	VBP	O
emerged	emerge	VBN	O
in	in	IN	O
the	the	DT	O
past	past	JJ	O
decade	decade	NN	B
,	,	,	B
,	,	,	O
traditional	traditional	JJ	O
anti	anti	JJ	O
-	-	JJ	O
T2D	t2d	JJ	O
agents	agent	NNS	O
such	such	JJ	O
as	as	IN	O
repaglinide	repaglinide	NN	O
,	,	,	O
metformin	metformin	NN	O
,	,	,	O
dipeptidyl	dipeptidyl	NNP	O
peptidase	peptidase	NNP	O
-	-	HYPH	O
IV	IV	NNP	O
inhibitors	inhibitor	NNS	O
,	,	,	O
Î±-glucosidase	î±-glucosidase	NN	O
inhibitors	inhibitor	NNS	O
and	and	CC	O
glucagon	glucagon	NN	O
-	-	HYPH	O
like	like	UH	O
peptide-1	peptide-1	NNP	O
agonists	agonist	NNS	O
,	,	,	O
and	and	CC	O
thiazolidinediones	thiazolidinedione	NNS	O
are	be	VBP	O
still	still	RB	O
the	the	DT	O
most	most	RBS	O
efficacious	efficacious	JJ	O
oral	oral	JJ	O
drugs	drug	NNS	O
in	in	IN	O
the	the	DT	O
first	first	JJ	O
-	-	HYPH	O
line	line	NN	O
monotherapy	monotherapy	NN	O
of	of	IN	O
T2D	t2d	NN	B
.	.	.	O

It	-PRON-	PRP	O
is	be	VBZ	O
undoubted	undoubted	JJ	O
that	that	IN	O
new	new	JJ	O
insulin	insulin	NN	O
sensitisers	sensitiser	NNS	O
will	will	MD	O
meet	meet	VB	O
great	great	JJ	O
needs	need	NNS	O
of	of	IN	O
T2D	t2d	NN	O
patients	patient	NNS	B
,	,	,	B
.	.	.	O

Protein	protein	NN	O
tyrosine	tyrosine	NN	O
phosphatase	phosphatase	NN	O
1B	1B	NNP	O
dephosphosphorylates	dephosphosphorylate	VBZ	O
the	the	DT	O
tyrosine	tyrosine	NN	O
-	-	HYPH	O
phosphorylated	phosphorylate	VBN	O
insulin	insulin	NN	O
receptor	receptor	NN	O
and	and	CC	O
the	the	DT	O
downstream	downstream	JJ	O
insulin	insulin	NN	O
receptor	receptor	NN	O
substrate	substrate	NN	O
to	to	IN	O
down	down	RB	O
regulate	regulate	VB	O
insulin	insulin	NN	O
transduction	transduction	NN	B
.	.	.	O

PTP1B	PTP1B	NNS	O
inhibitors	inhibitor	NNS	O
could	could	MD	O
potentially	potentially	RB	O
improve	improve	VB	O
insulin	insulin	NN	O
sensitivity	sensitivity	NN	O
and	and	CC	O
normalise	normalise	NN	O
glucose	glucose	NN	O
levels	level	NNS	O
and	and	CC	O
therefore	therefore	RB	O
could	could	MD	O
be	be	VB	O
a	a	DT	O
promising	promising	JJ	O
therapeutic	therapeutic	JJ	O
strategy	strategy	NN	O
in	in	IN	O
the	the	DT	O
T2D	t2d	NN	O
patients	patient	NNS	O
.	.	.	O

Recent	recent	JJ	O
studies	study	NNS	O
also	also	RB	O
identified	identify	VBD	O
the	the	DT	O
involvement	involvement	NN	O
of	of	IN	O
intra	intra	JJ	O
-	-	JJ	O
islet	islet	JJ	O
PTP1B	PTP1B	NNS	O
in	in	IN	O
the	the	DT	O
regulation	regulation	NN	O
of	of	IN	O
insulin	insulin	NN	O
release	release	NN	O
and	and	CC	O
reinforce	reinforce	VB	O
the	the	DT	O
potential	potential	NN	O
of	of	IN	O
PTP1B	PTP1B	NNP	O
inhibitors	inhibitor	NNS	O
for	for	IN	O
the	the	DT	O
treatment	treatment	NN	O
of	of	IN	O
beta	beta	NN	O
-	-	HYPH	O
cell	cell	NN	O
secretory	secretory	JJ	O
failure	failure	NN	O
in	in	IN	O
the	the	DT	O
pathogenesis	pathogenesis	NN	O
of	of	IN	O
T2D	t2d	NN	B
,	,	,	B
.	.	.	O

Besides	besides	RB	O
,	,	,	O
PTP1B	ptp1b	JJ	O
-	-	HYPH	O
mediated	mediate	VBN	O
dephosphorylation	dephosphorylation	NN	O
has	have	VBZ	O
been	be	VBN	O
implicated	implicate	VBN	O
in	in	IN	O
the	the	DT	O
development	development	NN	O
of	of	IN	O
diabetes	diabetes	NN	B
,	,	,	O
cancer	cancer	NN	B
,	,	,	O
hepatic	hepatic	JJ	O
fibrosis	fibrosis	NN	B
,	,	,	O
bacterial	bacterial	JJ	O
infection	infection	NN	B
,	,	,	O
rheumatoid	rheumatoid	VBP	O
arthritis	arthritis	NN	B
and	and	CC	O
hypertension	hypertension	NN	B
.	.	.	O

Many	many	JJ	O
PTP1B	PTP1B	NNS	O
inhibitors	inhibitor	NNS	O
have	have	VBP	O
been	be	VBN	O
reported	report	VBN	O
,	,	,	O
but	but	CC	O
the	the	DT	O
discovery	discovery	NN	O
of	of	IN	O
PTP1B	PTP1B	NNP	O
inhibitors	inhibitor	NNS	O
with	with	IN	O
superior	superior	JJ	O
cell	cell	NN	O
permeability	permeability	NN	O
and	and	CC	O
inÂ	inÂ	NNP	O
vivo	vivo	NNP	O
potency	potency	NN	O
is	be	VBZ	O
difficult	difficult	JJ	O
and	and	CC	O
so	so	RB	O
far	far	RB	O
there	there	EX	O
is	be	VBZ	O
no	no	DT	O
PTP1B	PTP1B	NNP	O
inhibitors	inhibitor	NNS	O
entered	enter	VBD	O
III	iii	CD	O
phase	phase	NN	O
clinical	clinical	JJ	O
trial	trial	NN	B
,	,	,	B
.	.	.	O

Hundreds	hundred	NNS	O
of	of	IN	O
natural	natural	JJ	O
products	product	NNS	O
have	have	VBP	O
been	be	VBN	O
isolated	isolate	VBN	O
and	and	CC	O
identified	identify	VBN	O
as	as	IN	O
PTP1B	PTP1B	NNP	O
inhibitors	inhibitor	NNS	O
,	,	,	O
and	and	CC	O
natural	natural	JJ	O
products	product	NNS	O
with	with	IN	O
interesting	interesting	JJ	O
structural	structural	JJ	O
diversity	diversity	NN	O
have	have	VBP	O
potential	potential	NN	O
to	to	TO	O
develop	develop	VB	O
the	the	DT	O
new	new	JJ	O
PTP1B	PTP1B	NNP	O
inhibitors	inhibitor	NNS	B
.	.	.	O

In	in	IN	O
our	-PRON-	PRP$	O
previous	previous	JJ	O
work	work	NN	O
,	,	,	O
some	some	DT	O
oleanolic	oleanolic	JJ	O
acid	acid	NN	O
derivatives	derivative	NNS	O
with	with	IN	O
modified	modified	JJ	O
A	a	NN	O
-	-	HYPH	O
ring	ring	NN	O
,	,	,	O
C	c	NN	O
-	-	HYPH	O
ring	ring	NN	O
,	,	,	O
and	and	CC	O
C17	C17	NNP	O
moiety	moiety	NN	O
were	be	VBD	O
designed	design	VBN	O
and	and	CC	O
synthesized	synthesize	VBN	B
.	.	.	O

Within	within	IN	O
these	these	DT	O
OA	OA	NNP	O
derivatives	derivative	NNS	O
,	,	,	O
compound	compound	NN	O
C10a	C10a	NNS	O
exhibited	exhibit	VBD	O
the	the	DT	O
most	most	JJS	O
PTP1B	ptp1b	NN	O
inhibition	inhibition	NN	O
IC50	ic50	NN	O
:	:	:	O
3.12âÎ¼M	3.12âî¼m	NN	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
7.6-fold	7.6-fold	CD	O
more	more	JJR	O
than	than	IN	O
the	the	DT	O
parent	parent	NN	O
compound	compound	NN	O
OA	OA	NNP	B
.	.	.	O

However	however	RB	O
,	,	,	O
the	the	DT	O
triterpenoid	triterpenoid	JJ	O
derivative	derivative	JJ	O
C10a	C10a	NNS	O
has	have	VBZ	O
too	too	RB	O
large	large	JJ	O
molecular	molecular	JJ	O
weight	weight	NN	O
and	and	CC	O
some	some	DT	O
pharmacological	pharmacological	JJ	O
defects	defect	NNS	O
,	,	,	O
such	such	JJ	O
as	as	IN	O
weak	weak	JJ	O
cell	cell	NN	O
permeability	permeability	NN	O
,	,	,	O
poor	poor	JJ	O
bioavailability	bioavailability	NN	O
and	and	CC	O
improper	improper	JJ	O
lipid	lipid	NN	O
/	/	SYM	O
water	water	NN	O
partition	partition	NN	O
coefficient	coefficient	NN	O
.	.	.	O

C10a	C10a	NNP	O
also	also	RB	O
showed	show	VBD	O
the	the	DT	O
considerable	considerable	JJ	O
cytotoxicity	cytotoxicity	NN	O
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
the	the	DT	O
structure	structure	NN	O
of	of	IN	O
C10a	C10a	NNS	O
needs	need	VBZ	O
to	to	TO	O
be	be	VB	O
optimised	optimise	VBN	O
to	to	TO	O
develop	develop	VB	O
the	the	DT	O
potent	potent	JJ	O
PTP1B	PTP1B	NNP	O
inhibitors	inhibitor	NNS	O
with	with	IN	O
favourable	favourable	JJ	O
pharmacological	pharmacological	JJ	O
properties	property	NNS	O
.	.	.	O

The	the	DT	O
chemical	chemical	NN	O
structures	structure	NNS	O
of	of	IN	O
OA	OA	NNP	O
and	and	CC	O
lead	lead	JJ	O
compound	compound	NN	O
C10a	C10a	NNS	O
.	.	.	O

The	the	DT	O
structural	structural	JJ	O
optimisation	optimisation	NN	O
strategy	strategy	NN	O
is	be	VBZ	O
shown	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
2	2	CD	O
.	.	.	O

The	the	DT	O
structure	structure	NN	O
of	of	IN	O
C10a	C10a	NNS	O
contains	contain	VBZ	O
hydrophobic	hydrophobic	JJ	O
scaffold	scaffold	NNP	O
,	,	,	O
linker	linker	NNP	O
and	and	CC	O
aryl	aryl	NNP	O
moiety	moiety	NN	O
.	.	.	O

As	as	IN	O
displayed	display	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
3	3	CD	O
,	,	,	O
the	the	DT	O
molecular	molecular	JJ	O
docking	docking	NN	O
has	have	VBZ	O
demonstrated	demonstrate	VBN	O
the	the	DT	O
hydrophobic	hydrophobic	JJ	O
interactions	interaction	NNS	O
between	between	IN	O
the	the	DT	O
terpenoid	terpenoid	JJ	O
scaffold	scaffold	NN	O
of	of	IN	O
C10a	C10a	NNS	O
and	and	CC	O
the	the	DT	O
surrounding	surround	VBG	O
amino	amino	JJ	O
residues	residue	NNS	O
of	of	IN	O
PTP1B	ptp1b	PRP	O
are	be	VBP	O
critical	critical	JJ	O
for	for	IN	O
the	the	DT	O
complex	complex	JJ	O
stability	stability	NN	O
,	,	,	O
but	but	CC	O
the	the	DT	O
pentacyclic	pentacyclic	JJ	O
core	core	NN	O
of	of	IN	O
C10a	C10a	NNS	O
is	be	VBZ	O
too	too	RB	O
complicated	complicated	JJ	O
.	.	.	O

We	-PRON-	PRP	O
assumed	assume	VBD	O
this	this	DT	O
scaffold	scaffold	NN	O
could	could	MD	O
be	be	VB	O
simplified	simplify	VBN	O
to	to	IN	O
the	the	DT	O
smaller	small	JJR	O
tricyclic	tricyclic	JJ	O
fragment	fragment	NN	O
containing	contain	VBG	O
the	the	DT	O
same	same	JJ	O
stereo	stereo	NN	O
-	-	HYPH	O
conformation	conformation	NN	O
of	of	IN	O
fused	fuse	VBN	O
A	a	NN	O
/	/	SYM	O
B	b	NN	O
ring	ring	NN	O
junction	junction	NN	O
,	,	,	O
such	such	JJ	O
as	as	IN	O
the	the	DT	O
tricyclic	tricyclic	JJ	O
terpenoid	terpenoid	JJ	O
scaffold	scaffold	NNP	O
of	of	IN	O
compound	compound	NNP	O
15	15	CD	O
as	as	IN	O
shown	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
3	3	CD	O
.	.	.	O

One	one	CD	O
of	of	IN	O
the	the	DT	O
methyl	methyl	NN	O
group	group	NN	O
at	at	IN	O
4-position	4-position	CD	O
also	also	RB	O
was	be	VBD	O
retained	retain	VBN	O
,	,	,	O
because	because	IN	O
it	-PRON-	PRP	O
was	be	VBD	O
beneficial	beneficial	JJ	O
for	for	IN	O
interaction	interaction	NN	O
with	with	IN	O
Arg24	Arg24	NNP	B
,	,	,	O
which	which	WDT	O
is	be	VBZ	O
an	an	DT	O
important	important	JJ	O
residue	residue	NN	O
at	at	IN	O
the	the	DT	O
second	second	JJ	O
site	site	NN	O
of	of	IN	O
PTP1B	ptp1b	PRP	O
for	for	IN	O
substrate	substrate	NN	O
specificity	specificity	NN	B
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
3	3	CD	O
,	,	,	O
C	C	NNP	O
ring	ring	NN	O
was	be	VBD	O
replaced	replace	VBN	O
with	with	IN	O
the	the	DT	O
substituted	substitute	VBN	O
benzene	benzene	NN	O
ring	ring	NN	O
,	,	,	O
which	which	WDT	O
could	could	MD	O
provide	provide	VB	O
opportunities	opportunity	NNS	O
to	to	TO	O
form	form	VB	O
more	more	JJR	O
hydrophobic	hydrophobic	JJ	O
and	and	CC	O
ÏâÏ	ïâï	CD	O
interactions	interaction	NNS	O
.	.	.	O

D	d	JJ	O
ring	ring	NN	O
and	and	CC	O
E	e	NN	O
ring	ring	NN	O
were	be	VBD	O
simplified	simplify	VBN	O
to	to	IN	O
the	the	DT	O
linker	linker	NN	O
from	from	IN	O
C	C	NNP	O
ring	ring	NN	O
to	to	IN	O
the	the	DT	O
aryl	aryl	NNP	O
moiety	moiety	NN	O
.	.	.	O

Insertion	insertion	NN	O
of	of	IN	O
polar	polar	JJ	O
group	group	NN	O
into	into	IN	O
this	this	DT	O
linker	linker	NN	O
would	would	MD	O
be	be	VB	O
beneficial	beneficial	JJ	O
for	for	IN	O
the	the	DT	O
favourable	favourable	JJ	O
balance	balance	NN	O
between	between	IN	O
hydrophilicity	hydrophilicity	NN	O
and	and	CC	O
hydrophobicity	hydrophobicity	NN	O
.	.	.	O

The	the	DT	O
overlapping	overlap	VBG	O
figure	figure	NN	O
of	of	IN	O
C10a	C10a	NNS	O
and	and	CC	O
15	15	CD	O
indicated	indicate	VBD	O
these	these	DT	O
compounds	compound	NNS	O
have	have	VBP	O
similar	similar	JJ	O
docking	docking	NN	O
modes	mode	NNS	O
with	with	IN	O
amino	amino	JJ	O
residues	residue	NNS	O
of	of	IN	O
PTP1B	PTP1B	NNP	O
Figure	Figure	NNP	O
3	3	CD	O
.	.	.	O

Only	only	RB	O
two	two	CD	O
hydrogen	hydrogen	NN	O
-	-	HYPH	O
bond	bond	NN	O
interactions	interaction	NNS	O
between	between	IN	O
C10a	C10a	NNS	O
and	and	CC	O
PTP1B	ptp1b	PRP	O
were	be	VBD	O
observed	observe	VBN	O
,	,	,	O
so	so	RB	O
the	the	DT	O
aryl	aryl	NNP	O
moiety	moiety	NN	O
of	of	IN	O
C10a	C10a	NNS	O
was	be	VBD	O
replaced	replace	VBN	O
with	with	IN	O
various	various	JJ	O
substituted	substitute	VBN	O
rings	ring	NNS	O
in	in	IN	O
order	order	NN	O
to	to	TO	O
enhance	enhance	VB	O
inhibition	inhibition	NN	O
,	,	,	O
since	since	IN	O
the	the	DT	O
aryl	aryl	NNP	O
moiety	moiety	NNP	O
was	be	VBD	O
important	important	JJ	O
for	for	IN	O
the	the	DT	O
substrate	substrate	JJ	O
recognition	recognition	NN	B
.	.	.	O

The	the	DT	O
structural	structural	JJ	O
optimisation	optimisation	NN	O
strategy	strategy	NN	O
.	.	.	O

C10a	C10a	NNP	O
and	and	CC	O
15	15	CD	O
docked	dock	VBN	O
in	in	IN	O
the	the	DT	O
PTP1B	PTP1B	NNP	O
active	active	JJ	O
site	site	NN	O
.	.	.	O

Only	only	RB	O
the	the	DT	O
active	active	JJ	O
site	site	NN	O
was	be	VBD	O
shown	show	VBN	O
,	,	,	O
displaying	display	VBG	O
the	the	DT	O
protein	protein	NN	O
in	in	IN	O
surface	surface	NN	O
representation	representation	NN	O
and	and	CC	O
ligand	ligand	NNP	O
C10a	C10a	NNS	O
in	in	IN	O
stick	stick	NN	O
representation	representation	NN	O
;	;	:	O
C10a	C10a	NNS	O
,	,	,	O
Coloured	coloured	JJ	O
green	green	NN	O
and	and	CC	O
displayed	display	VBD	O
in	in	IN	O
stick	stick	NN	O
representation	representation	NN	O
,	,	,	O
bound	bind	VBN	O
to	to	IN	O
these	these	DT	O
important	important	JJ	O
residues	residue	NNS	O
in	in	IN	O
the	the	DT	O
interior	interior	NN	O
of	of	IN	O
the	the	DT	O
active	active	JJ	O
site	site	NN	O
.	.	.	O

All	all	DT	O
hydrogen	hydrogen	NN	O
atoms	atom	NNS	O
are	be	VBP	O
omitted	omit	VBN	O
for	for	IN	O
clarity	clarity	NN	O
;	;	:	O
15	15	CD	O
bound	bind	VBN	O
to	to	IN	O
the	the	DT	O
important	important	JJ	O
residues	residue	NNS	O
in	in	IN	O
the	the	DT	O
interior	interior	NN	O
of	of	IN	O
the	the	DT	O
active	active	JJ	O
site	site	NN	O
;	;	:	O
The	the	DT	O
overlapping	overlap	VBG	O
docking	docking	NN	O
modes	mode	NNS	O
of	of	IN	O
C10a	C10a	NNS	O
and	and	CC	O
15	15	CD	O
.	.	.	O

The	the	DT	O
synthesis	synthesis	NN	O
procedure	procedure	NN	O
to	to	TO	O
achieve	achieve	VB	O
15-hydroxydehydroabietic	15-hydroxydehydroabietic	CD	O
acid	acid	NN	O
from	from	IN	O
abietic	abietic	JJ	O
acid	acid	NN	O
involved	involve	VBN	O
addition	addition	NN	O
,	,	,	O
elimination	elimination	NN	O
,	,	,	O
and	and	CC	O
oxidation	oxidation	NN	O
.	.	.	O

However	however	RB	O
,	,	,	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
literatures	literature	NNS	B
,	,	,	O
alcohol	alcohol	NN	O
3	3	CD	O
was	be	VBD	O
obtained	obtain	VBN	O
in	in	IN	O
only	only	RB	O
10	10	CD	O
%	%	NN	O
yield	yield	NN	O
in	in	IN	O
our	-PRON-	PRP$	O
laboratory	laboratory	NN	O
.	.	.	O

We	-PRON-	PRP	O
therefore	therefore	RB	O
improved	improve	VBD	O
the	the	DT	O
synthetic	synthetic	JJ	O
method	method	NN	O
and	and	CC	O
3	3	CD	O
was	be	VBD	O
finally	finally	RB	O
obtained	obtain	VBN	O
in	in	IN	O
70	70	CD	O
%	%	NN	O
overall	overall	JJ	O
yield	yield	NN	O
.	.	.	O

According	accord	VBG	O
to	to	IN	O
the	the	DT	O
improved	improve	VBN	O
synthetic	synthetic	JJ	O
procedure	procedure	NN	O
,	,	,	O
AA	AA	NNP	O
was	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
33	33	CD	O
%	%	NN	O
HBr	HBr	NNS	O
/	/	SYM	O
AcOH	acoh	NN	O
and	and	CC	O
the	the	DT	O
resulting	result	VBG	O
8	8	CD	O
,	,	,	O
15-dibromo	15-dibromo	CD	O
derivative	derivative	NN	O
was	be	VBD	O
heated	heat	VBN	O
in	in	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
LiOH	LiOH	NNP	O
/	/	SYM	O
DMF	DMF	NNP	O
to	to	TO	O
afford	afford	VB	O
diene	diene	NNP	O
,	,	,	O
with	with	IN	O
four	four	CD	O
methyl	methyl	NN	O
groups	group	NNS	O
of	of	IN	O
all	all	DT	O
singlets	singlet	NNS	O
by	by	IN	O
1HNMR	1hnmr	CD	O
.	.	.	O

Oxidative	oxidative	JJ	O
rearrangement	rearrangement	NN	O
of	of	IN	O
2	2	CD	O
with	with	IN	O
SeO2	SeO2	NNS	O
provided	provide	VBN	O
15-hydroxydehydroabietate	15-hydroxydehydroabietate	CD	O
in	in	IN	O
80	80	CD	O
%	%	NN	O
yield	yield	NN	O
.	.	.	O

3	3	CD	O
was	be	VBD	O
esterified	esterify	VBN	O
by	by	IN	O
treatment	treatment	NN	O
with	with	IN	O
EtI	EtI	NNP	O
to	to	TO	O
give	give	VB	O
ester	ester	NN	O
4a	4a	CD	O
4âb	4âb	CD	O
.	.	.	O

4a	4a	NNP	O
was	be	VBD	O
then	then	RB	O
reduced	reduce	VBN	O
with	with	IN	O
LiAlH4	LiAlH4	NNP	O
to	to	TO	O
give	give	VB	O
alcohol	alcohol	NN	O
5	5	CD	O
.	.	.	O

We	-PRON-	PRP	O
found	find	VBD	O
15-hydroxydehydroabietic	15-hydroxydehydroabietic	CD	O
derivatives	derivative	NNS	O
are	be	VBP	O
not	not	RB	O
suitable	suitable	JJ	O
synthesis	synthesis	NN	O
intermediates	intermediate	NNS	O
because	because	IN	O
of	of	IN	O
high	high	JJ	O
steric	steric	JJ	O
hindrance	hindrance	NN	O
of	of	IN	O
C-15	c-15	CD	O
position	position	NN	O
,	,	,	O
and	and	CC	O
thus	thus	RB	O
hydroperoxide	hydroperoxide	JJ	O
rearrangement	rearrangement	NN	O
of	of	IN	O
esters	ester	NNS	O
4aâb	4aâb	CD	O
with	with	IN	O
t	t	NNP	O
-	-	HYPH	O
BuOOH	BuOOH	NNP	O
and	and	CC	O
H2SO4	H2SO4	NNP	O
/	/	SYM	O
AcOH	AcOH	NNP	O
gave	give	VBD	O
the	the	DT	O
13-hydroxy-8,11,13-podocarpatriene	13-hydroxy-8,11,13-podocarpatriene	CD	O
derivatives	derivative	NNS	O
6aâb	6aâb	NN	O
)	)	-RRB-	B
.	.	.	O

Finally	finally	RB	O
,	,	,	O
ester	ester	NN	O
6a	6a	NNP	O
was	be	VBD	O
saponified	saponify	VBN	O
with	with	IN	O
aq	aq	NNP	O
.	.	.	O

NaOH	NaOH	NNP	O
to	to	TO	O
give	give	VB	O
acid	acid	NN	O
7	7	CD	O
.	.	.	O

Synthesis	synthesis	NN	O
of	of	IN	O
the	the	DT	O
compounds	compound	NNS	O
2â7	2â7	CD	O
.	.	.	O

A	a	DT	O
couple	couple	NN	O
of	of	IN	O
methyl	methyl	NN	O
groups	group	NNS	O
at	at	IN	O
4-position	4-position	CD	O
is	be	VBZ	O
most	most	RBS	O
frequently	frequently	RB	O
found	find	VBN	O
in	in	IN	O
the	the	DT	O
terpenoid	terpenoid	NN	O
scaffold	scaffold	NN	O
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Scheme	Scheme	NNP	O
2	2	CD	O
,	,	,	O
the	the	DT	O
conversion	conversion	NN	O
of	of	IN	O
the	the	DT	O
COOH	COOH	NNP	O
at	at	IN	O
4-position	4-position	CD	O
to	to	IN	O
CH3	CH3	NNP	O
was	be	VBD	O
also	also	RB	O
investigated	investigate	VBN	O
.	.	.	O

Acids	acid	NNS	O
1	1	CD	O
and	and	CC	O
2	2	CD	O
were	be	VBD	O
firstly	firstly	RB	O
esterified	esterify	VBN	O
by	by	IN	O
treatment	treatment	NN	O
with	with	IN	O
EtI	EtI	NNP	O
and	and	CC	O
K2CO3	K2CO3	NNP	O
to	to	TO	O
give	give	VB	O
corresponding	corresponding	JJ	O
esters	ester	NNS	O
,	,	,	O
which	which	WDT	O
were	be	VBD	O
subsequently	subsequently	RB	O
reduced	reduce	VBN	O
to	to	TO	O
afford	afford	VB	O
alcohols	alcohol	NNS	O
.	.	.	O

Conversion	conversion	NN	O
of	of	IN	O
alcohols	alcohol	NNS	O
to	to	IN	O
its	-PRON-	PRP$	O
tosylates	tosylate	NNS	O
in	in	IN	O
pyridine	pyridine	NNP	O
proceeded	proceed	VBN	O
in	in	IN	O
satisfactory	satisfactory	JJ	O
yield	yield	NN	O
.	.	.	O

Zn	Zn	NNP	O
/	/	SYM	O
NaI	NaI	NNP	O
reduction	reduction	NN	B
of	of	IN	O
abietane	abietane	NN	O
-	-	HYPH	O
tosylates	tosylate	NNS	O
afforded	afford	VBN	O
dienes	diene	NNS	O
11â12	11â12	NNS	O
in	in	IN	O
satisfactory	satisfactory	JJ	O
yield	yield	NN	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

Then	then	RB	O
,	,	,	O
diene	diene	NNP	O
12	12	CD	O
was	be	VBD	O
oxidative	oxidative	CD	O
rearranged	rearrange	VBN	O
with	with	IN	O
SeO2	SeO2	NNS	O
to	to	TO	O
obtain	obtain	VB	O
alcohol	alcohol	NN	O
13	13	CD	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
converted	convert	VBN	O
to	to	IN	O
phenol	phenol	NNP	O
14	14	CD	O
by	by	IN	O
hydroperoxide	hydroperoxide	JJ	O
rearrangement	rearrangement	NN	O
.	.	.	O

Synthesis	synthesis	NN	O
of	of	IN	O
the	the	DT	O
compounds	compound	NNS	O
8â14	8â14	CD	O
.	.	.	O

The	the	DT	O
final	final	JJ	O
products	product	NNS	O
15â34	15â34	CD	O
were	be	VBD	O
synthesised	synthesise	VBN	O
via	via	IN	O
nucleophilic	nucleophilic	JJ	O
substitution	substitution	NN	O
of	of	IN	O
6âb	6âb	CD	O
and	and	CC	O
corresponding	correspond	VBG	O
tosylate	tosylate	NN	O
or	or	CC	O
alkyl	alkyl	NN	O
bromide	bromide	NN	O
,	,	,	O
and	and	CC	O
subsequent	subsequent	JJ	O
deprotection	deprotection	NN	O
of	of	IN	O
O	o	NN	O
-	-	HYPH	O
protected	protect	VBN	O
intermediates	intermediate	NNS	O
Scheme	scheme	NN	O
3(AâC	3(aâc	CD	O
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Scheme	Scheme	NNP	O
3	3	CD	O
,	,	,	O
the	the	DT	O
tosylate	tosylate	NN	O
intermediates	intermediate	NNS	O
of	of	IN	O
15â19	15â19	NNP	O
and	and	CC	O
25â34	25â34	NNP	O
were	be	VBD	O
provided	provide	VBN	O
from	from	IN	O
corresponding	correspond	VBG	O
alcohols	alcohol	NNS	O
,	,	,	O
which	which	WDT	O
were	be	VBD	O
synthesised	synthesise	VBN	O
via	via	IN	O
condensation	condensation	NN	O
of	of	IN	O
the	the	DT	O
acids	acid	NNS	O
with	with	IN	O
different	different	JJ	O
rings	ring	NNS	O
and	and	CC	O
diols	diol	NNS	O
with	with	IN	O
different	different	JJ	O
length	length	NN	O
in	in	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
DCC	DCC	NNP	O
/	/	SYM	O
DMAP	DMAP	NNP	O
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Scheme	Scheme	NNP	O
3	3	CD	O
,	,	,	O
the	the	DT	O
tosylate	tosylate	NN	O
intermediates	intermediate	NNS	O
of	of	IN	O
20â23	20â23	CD	O
were	be	VBD	O
provided	provide	VBN	O
from	from	IN	O
corresponding	correspond	VBG	O
alcohols	alcohol	NNS	O
,	,	,	O
which	which	WDT	O
were	be	VBD	O
synthesised	synthesise	VBN	O
via	via	IN	O
nucleophilic	nucleophilic	JJ	O
substitution	substitution	NN	O
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Scheme	Scheme	NNP	O
3	3	CD	O
,	,	,	O
the	the	DT	O
alkyl	alkyl	NN	O
bromide	bromide	NN	O
intermediate	intermediate	NN	O
of	of	IN	O
24	24	CD	O
was	be	VBD	O
synthesised	synthesise	VBN	O
from	from	IN	O
the	the	DT	O
phenol	phenol	NNP	O
and	and	CC	O
bromoacetyl	bromoacetyl	NNP	O
bromide	bromide	NNP	O
in	in	IN	O
alkaline	alkaline	JJ	O
condition	condition	NN	O
.	.	.	O

Synthesis	Synthesis	NNP	O
of	of	IN	O
the	the	DT	O
compounds	compound	NNS	O
15â34	15â34	CD	O
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Table	table	NN	O
1	1	CD	O
,	,	,	O
the	the	DT	O
PTP1B	PTP1B	NNP	O
inhibitory	inhibitory	JJ	O
activities	activity	NNS	O
of	of	IN	O
abietic	abietic	JJ	O
derivatives	derivative	NNS	O
with	with	IN	O
two	two	CD	O
types	type	NNS	O
of	of	IN	O
terpenoid	terpenoid	NN	O
scaffolds	scaffold	NNS	O
were	be	VBD	O
firstly	firstly	RB	O
evaluated	evaluate	VBN	O
.	.	.	O

Structureâactivity	structureâactivity	NN	O
relationship	relationship	NN	O
was	be	VBD	O
also	also	RB	O
discussed	discuss	VBN	O
.	.	.	O

The	the	DT	O
carboxyl	carboxyl	NN	O
group	group	NN	O
at	at	IN	O
4-position	4-position	CD	O
was	be	VBD	O
beneficial	beneficial	JJ	O
for	for	IN	O
PTP1B	ptp1b	PRP	O
inhibition	inhibition	NN	O
.	.	.	O

Esterification	esterification	NN	O
of	of	IN	O
the	the	DT	O
carboxyl	carboxyl	NN	O
group	group	NN	O
to	to	TO	O
give	give	VB	O
corresponding	correspond	VBG	O
ethyl	ethyl	NN	O
ester	ester	NN	O
,	,	,	O
or	or	CC	O
reduction	reduction	NN	O
to	to	IN	O
the	the	DT	O
corresponding	correspond	VBG	O
alcohol	alcohol	NN	O
all	all	DT	O
resulted	result	VBD	O
in	in	IN	O
loss	loss	NN	O
of	of	IN	O
activity	activity	NN	O
.	.	.	O

Replacing	replace	VBG	O
the	the	DT	O
carboxyl	carboxyl	NN	O
group	group	NN	O
at	at	IN	O
4-position	4-position	CD	O
with	with	IN	O
methyl	methyl	NN	O
group	group	NN	O
resulted	result	VBD	O
in	in	IN	O
significant	significant	JJ	O
drop	drop	NN	O
in	in	IN	O
activity	activity	NN	O
.	.	.	O

Besides	besides	RB	O
,	,	,	O
transformation	transformation	NN	O
of	of	IN	O
hydroxy	hydroxy	NNP	O
isopropyl	isopropyl	NNP	O
group	group	NNP	O
at	at	IN	O
13-position	13-position	CD	O
of	of	IN	O
8,11,13-podocarpatriene	8,11,13-podocarpatriene	CD	O
derivatives	derivative	NNS	O
to	to	IN	O
hydroxy	hydroxy	NNP	O
group	group	NNP	O
resulted	result	VBD	O
in	in	IN	O
loss	loss	NN	O
of	of	IN	O
activity	activity	NN	O
.	.	.	O

The	the	DT	O
PTP1B	PTP1B	NNP	O
inhibitory	inhibitory	JJ	O
activities	activity	NNS	O
of	of	IN	O
abietic	abietic	JJ	O
derivatives	derivative	NNS	O
1â14	1â14	CD	O
.	.	.	O

These	these	DT	O
experiments	experiment	NNS	O
were	be	VBD	O
performed	perform	VBN	O
in	in	IN	O
triplicate	triplicate	NN	O
.	.	.	O

Among	among	IN	O
tricyclic	tricyclic	JJ	O
derivatives	derivative	NNS	O
15â34	15â34	CD	O
,	,	,	O
the	the	DT	O
compounds	compound	NNS	O
15	15	CD	O
2.9âÎ¼M	2.9âî¼m	CD	O
,	,	,	O
28	28	CD	O
4.8âÎ¼M	4.8âî¼m	NN	O
and	and	CC	O
34	34	CD	O
8.2âÎ¼M	8.2âî¼m	NN	O
exhibited	exhibit	VBD	O
the	the	DT	O
most	most	JJS	O
PTP1B	ptp1b	JJ	O
enzymatic	enzymatic	JJ	O
inhibitory	inhibitory	JJ	O
activities	activity	NNS	O
,	,	,	O
which	which	WDT	O
were	be	VBD	O
equal	equal	JJ	O
to	to	IN	O
that	that	DT	O
of	of	IN	O
the	the	DT	O
lead	lead	JJ	O
compound	compound	NN	O
C10a	C10a	NNS	O
3.1âÎ¼M	3.1âî¼m	CD	O
,	,	,	O
and	and	CC	O
they	-PRON-	PRP	O
have	have	VBP	O
smaller	small	JJR	O
molecular	molecular	JJ	O
weight	weight	NN	O
.	.	.	O

SAR	SAR	NNP	O
analysis	analysis	NN	O
demonstrated	demonstrate	VBD	O
that	that	IN	O
the	the	DT	O
derivatives	derivative	NNS	O
with	with	IN	O
different	different	JJ	O
linker	linker	NN	O
between	between	IN	O
terpenoid	terpenoid	NNP	O
scaffold	scaffold	NN	O
and	and	CC	O
ring	ring	NN	O
moiety	moiety	NN	O
displayed	display	VBD	O
different	different	JJ	O
PTP1B	PTP1B	NNS	O
inhibition	inhibition	NN	O
activity	activity	NN	O
.	.	.	O

The	the	DT	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
of	of	IN	O
PTP1B	ptp1b	PRP	O
decreased	decrease	VBN	O
along	along	RP	O
with	with	IN	O
an	an	DT	O
increase	increase	NN	O
of	of	IN	O
the	the	DT	O
length	length	NN	O
of	of	IN	O
linker	linker	NN	O
15â>â16â>â17	15â>â16â>â17	CD	O
.	.	.	O

Also	also	RB	O
,	,	,	O
the	the	DT	O
structure	structure	NN	O
of	of	IN	O
the	the	DT	O
linker	linker	NN	O
influenced	influence	VBN	O
PTP1B	ptp1b	PRP	O
inhibition	inhibition	NN	O
.	.	.	O

Compared	compare	VBN	O
with	with	IN	O
20	20	CD	O
and	and	CC	O
24	24	CD	O
,	,	,	O
15	15	CD	O
displayed	display	VBD	O
higher	high	JJR	O
PTP1B	ptp1b	NN	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
.	.	.	O

Besides	besides	RB	O
,	,	,	O
the	the	DT	O
derivatives	derivative	NNS	O
containing	contain	VBG	O
a	a	DT	O
benzene	benzene	NN	O
or	or	CC	O
naphthalene	naphthalene	NN	O
at	at	IN	O
the	the	DT	O
ring	ring	NN	O
moiety	moiety	NN	O
15	15	CD	O
,	,	,	O
18â19	18â19	CD	O
,	,	,	O
25â28	25â28	CD	O
and	and	CC	O
34	34	CD	O
showed	show	VBD	O
higher	high	JJR	O
inhibitory	inhibitory	NN	O
activity	activity	NN	O
relative	relative	JJ	O
to	to	IN	O
the	the	DT	O
analogues	analogue	NNS	O
bearing	bear	VBG	O
the	the	DT	O
heteroaromatic	heteroaromatic	JJ	O
ring	ring	NN	O
or	or	CC	O
alicyclic	alicyclic	NN	O
ring	ring	NN	O
31â33	31â33	NNP	O
.	.	.	O

At	at	IN	O
the	the	DT	O
ring	ring	NN	O
moiety	moiety	NN	O
,	,	,	O
a	a	DT	O
clear	clear	JJ	O
preference	preference	NN	O
was	be	VBD	O
identified	identify	VBN	O
for	for	IN	O
the	the	DT	O
polar	polar	JJ	O
groups	group	NNS	O
,	,	,	O
with	with	IN	O
an	an	DT	O
increase	increase	NN	O
in	in	IN	O
activity	activity	NN	O
for	for	IN	O
the	the	DT	O
carboxyl	carboxyl	NN	O
group	group	NNP	O
and	and	CC	O
amino	amino	NNP	O
group	group	NN	O
,	,	,	O
whereas	whereas	IN	O
substitution	substitution	NN	O
with	with	IN	O
carboxylmethyl	carboxylmethyl	NNP	O
group	group	NN	O
led	lead	VBD	O
to	to	IN	O
significant	significant	JJ	O
loss	loss	NN	O
of	of	IN	O
activity	activity	NN	O
.	.	.	O

The	the	DT	O
benzene	benzene	NN	O
ring	re	VBG	O
with	with	IN	O
a	a	DT	O
carboxyl	carboxyl	NN	O
group	group	NN	O
at	at	IN	O
the	the	DT	O
o	o	NN	O
-	-	HYPH	O
position	position	NN	O
increased	increase	VBD	O
the	the	DT	O
potency	potency	NN	O
relative	relative	JJ	O
to	to	IN	O
those	those	DT	O
at	at	IN	O
the	the	DT	O
p	p	NN	O
-	-	HYPH	O
position	position	NN	O
or	or	CC	O
m	m	NN	O
-	-	HYPH	O
position	position	NN	O
.	.	.	O

Overall	overall	RB	O
,	,	,	O
our	-PRON-	PRP$	O
data	datum	NNS	O
demonstrated	demonstrate	VBD	O
these	these	DT	O
compounds	compound	NNS	O
with	with	IN	O
tricyclic	tricyclic	JJ	O
diterpene	diterpene	NN	O
moiety	moiety	NN	O
are	be	VBP	O
potent	potent	JJ	O
PTP1B	PTP1B	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

The	the	DT	O
PTP1B	PTP1B	NNP	O
inhibitory	inhibitory	JJ	O
activities	activity	NNS	O
of	of	IN	O
tricyclic	tricyclic	JJ	O
derivatives	derivative	NNS	O
15â34	15â34	CD	O
.	.	.	O

These	these	DT	O
experiments	experiment	NNS	O
were	be	VBD	O
performed	perform	VBN	O
in	in	IN	O
triplicate	triplicate	NN	O
.	.	.	O

SD	sd	NN	O
:	:	:	O
standard	standard	JJ	O
deviation	deviation	NN	O
.	.	.	O

To	to	TO	O
assess	assess	VB	O
the	the	DT	O
insulin	insulin	NN	O
sensitisation	sensitisation	NN	O
,	,	,	O
the	the	DT	O
cellular	cellular	JJ	O
effect	effect	NN	O
of	of	IN	O
these	these	DT	O
compounds	compound	NNS	O
on	on	IN	O
insulin	insulin	NN	O
-	-	HYPH	O
resistant	resistant	JJ	O
human	human	JJ	O
hepatoma	hepatoma	NN	O
HepG2	HepG2	NNP	O
cells	cell	NNS	O
was	be	VBD	O
performed	perform	VBN	O
.	.	.	O

The	the	DT	O
concentration	concentration	NN	O
of	of	IN	O
insulin	insulin	NN	O
and	and	CC	O
induction	induction	NN	O
time	time	NN	O
were	be	VBD	O
screened	screen	VBN	O
to	to	TO	O
induce	induce	VB	O
insulin	insulin	NN	O
resistance	resistance	NN	O
in	in	IN	O
HepG2	HepG2	NNP	O
cells	cell	NNS	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
reported	report	VBN	O
method	method	NN	B
,	,	,	B
with	with	IN	O
some	some	DT	O
modification	modification	NN	O
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
4	4	CD	O
,	,	,	O
treatment	treatment	NN	O
with	with	IN	O
above	above	JJ	O
1âÃâ10â5âmmol	1âãâ10â5âmmol	CD	O
of	of	IN	O
insulin	insulin	NN	O
reduced	reduce	VBN	O
glucose	glucose	NNP	O
uptake	uptake	JJ	O
,	,	,	O
whereas	whereas	IN	O
treatment	treatment	NN	O
with	with	IN	O
6âÃâ10â6âmmol	6âãâ10â6âmmol	CD	O
of	of	IN	O
insulin	insulin	NN	O
enhanced	enhance	VBN	O
glucose	glucose	NNP	O
uptake	uptake	JJ	O
.	.	.	O

Insulin	insulin	NN	O
resistance	resistance	NN	O
can	can	MD	O
be	be	VB	O
obviously	obviously	RB	O
observed	observe	VBN	O
when	when	WRB	O
the	the	DT	O
HepG2	HepG2	NNP	O
cells	cell	NNS	O
were	be	VBD	O
treatment	treatment	NN	O
with	with	IN	O
1.5âÃâ10â5âmmol	1.5âãâ10â5âmmol	CD	O
of	of	IN	O
insulin	insulin	NN	O
,	,	,	O
and	and	CC	O
an	an	DT	O
insulin	insulin	NN	O
sensitiser	sensitiser	NN	O
can	can	MD	O
significantly	significantly	RB	O
decrease	decrease	VB	O
the	the	DT	O
insulin	insulin	NN	O
resistance	resistance	NN	O
and	and	CC	O
improve	improve	VB	O
the	the	DT	O
glucose	glucose	NN	O
uptake	uptake	NN	O
.	.	.	O

Treatment	treatment	NN	O
with	with	IN	O
higher	high	JJR	O
concentration	concentration	NN	O
>	>	XX	O
2âÃâ10â5âmmol	2âãâ10â5âmmol	CD	O
of	of	IN	O
insulin	insulin	NN	O
inhibited	inhibited	JJ	O
cell	cell	NN	O
growth	growth	NN	O
,	,	,	O
and	and	CC	O
microscopic	microscopic	JJ	O
examination	examination	NN	O
revealed	reveal	VBD	O
atrophy	atrophy	NN	O
of	of	IN	O
the	the	DT	O
cells	cell	NNS	O
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
4	4	CD	O
,	,	,	O
insulin	insulin	NN	O
resistance	resistance	NN	O
was	be	VBD	O
induced	induce	VBN	O
in	in	IN	O
HepG2	HepG2	NNP	O
cells	cell	NNS	O
at	at	IN	O
36âh	36âh	CD	O
,	,	,	O
and	and	CC	O
rosiglitazone	rosiglitazone	NN	O
can	can	MD	O
decrease	decrease	VB	O
the	the	DT	O
insulin	insulin	NN	O
resistance	resistance	NN	O
.	.	.	O

The	the	DT	O
cell	cell	NN	O
growth	growth	NN	O
was	be	VBD	O
accelerated	accelerate	VBN	O
after	after	IN	O
36âh	36âh	CD	O
and	and	CC	O
insulin	insulin	NN	O
resistance	resistance	NN	O
was	be	VBD	O
decreased	decrease	VBN	O
along	along	IN	O
with	with	IN	O
induction	induction	NN	O
time	time	NN	O
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
the	the	DT	O
cells	cell	NNS	O
were	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
1.5âÃâ1	1.5âãâ1	CD	O
0	0	CD	O
â5âmmol	â5âmmol	NNP	O
of	of	IN	O
insulin	insulin	NN	O
for	for	IN	O
36âh	36âh	CD	O
to	to	TO	O
induce	induce	VB	O
the	the	DT	O
insulin	insulin	NN	O
resistance	resistance	NN	O
and	and	CC	O
produce	produce	VB	O
the	the	DT	O
most	most	RBS	O
obvious	obvious	JJ	O
difference	difference	NN	O
of	of	IN	O
glucose	glucose	VB	O
consumption	consumption	NN	O
between	between	IN	O
insulin	insulin	NNP	O
resistance	resistance	NNP	O
group	group	NNP	O
and	and	CC	O
rosiglitazone	rosiglitazone	NN	O
group	group	NN	O
.	.	.	O

The	the	DT	O
effect	effect	NN	O
of	of	IN	O
the	the	DT	O
compounds	compound	NNS	O
on	on	IN	O
glucose	glucose	NNP	O
consumption	consumption	NN	O
in	in	IN	O
insulin	insulin	NN	O
-	-	HYPH	O
resistant	resistant	JJ	O
HepG2	HepG2	NNP	O
cells	cell	NNS	O
.	.	.	O

The	the	DT	O
HepG2	HepG2	NNP	O
cells	cell	NNS	O
were	be	VBD	O
induced	induce	VBN	O
with	with	IN	O
different	different	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
insulin	insulin	NN	O
;	;	:	O
The	the	DT	O
HepG2	HepG2	NNP	O
cells	cell	NNS	O
were	be	VBD	O
induced	induce	VBN	O
for	for	IN	O
different	different	JJ	O
induction	induction	NN	O
times	time	NNS	O
;	;	:	O
HepG2	HepG2	NNP	O
cells	cell	NNS	O
were	be	VBD	O
induced	induce	VBN	O
with	with	IN	O
1.5âÃâ10â5âmmol	1.5âãâ10â5âmmol	CD	O
of	of	IN	O
insulin	insulin	NN	O
for	for	IN	O
36âh	36âh	CD	O
to	to	TO	O
afford	afford	VB	O
insulin	insulin	NN	O
-	-	HYPH	O
resistant	resistant	JJ	O
cells	cell	NNS	O
,	,	,	O
and	and	CC	O
then	then	RB	O
treated	treat	VBN	O
with	with	IN	O
rosiglitazone	rosiglitazone	NN	O
or	or	CC	O
the	the	DT	O
compounds	compound	NNS	O
for	for	IN	O
24âh	24âh	CD	O
.	.	.	O

After	after	IN	O
incubation	incubation	NN	O
,	,	,	O
glucose	glucose	VBP	O
content	content	NN	O
in	in	IN	O
the	the	DT	O
culture	culture	NN	O
medium	medium	NN	O
was	be	VBD	O
measured	measure	VBN	O
by	by	IN	O
glucose	glucose	NNP	O
oxidase	oxidase	NN	O
method	method	NN	O
.	.	.	O

M	M	NNP	O
group	group	NN	O
:	:	:	O
insulin	insulin	NN	O
-	-	HYPH	O
resistant	resistant	JJ	O
HepG2	HepG2	NNP	O
cells	cell	NNS	O
without	without	IN	O
rosiglitazone	rosiglitazone	NN	O
and	and	CC	O
the	the	DT	O
compounds	compound	NNS	O
;	;	:	O
K	K	NNP	O
group	group	NN	O
:	:	:	O
HepG2	hepg2	NN	O
cells	cell	NNS	O
without	without	IN	O
induction	induction	NN	O
by	by	IN	O
insulin	insulin	NN	O
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
4	4	CD	O
,	,	,	O
most	most	JJS	O
compounds	compound	NNS	O
can	can	MD	O
enhance	enhance	VB	O
the	the	DT	O
glucose	glucose	NN	O
consumption	consumption	NN	O
in	in	IN	O
insulin	insulin	NN	O
-	-	HYPH	O
resistant	resistant	JJ	O
HepG2	HepG2	NNP	O
cells	cell	NNS	O
,	,	,	O
and	and	CC	O
the	the	DT	O
insulin	insulin	NN	O
stimulatory	stimulatory	JJ	O
effects	effect	NNS	O
on	on	IN	O
glucose	glucose	NNP	O
uptake	uptake	NNP	O
were	be	VBD	O
similar	similar	JJ	O
to	to	IN	O
that	that	DT	O
of	of	IN	O
C10a	C10a	NNS	O
,	,	,	O
but	but	CC	O
inferior	inferior	JJ	O
to	to	IN	O
that	that	DT	O
of	of	IN	O
rosiglitazone	rosiglitazone	NN	O
.	.	.	O

Cell	cell	NN	O
viability	viability	NN	O
was	be	VBD	O
evaluated	evaluate	VBN	O
with	with	IN	O
the	the	DT	O
MTT	MTT	NNP	O
assay	assay	NN	O
and	and	CC	O
the	the	DT	O
result	result	NN	O
demonstrated	demonstrate	VBD	O
that	that	IN	O
the	the	DT	O
cytotoxicities	cytotoxicity	NNS	O
of	of	IN	O
most	most	JJS	O
compounds	compound	NNS	O
were	be	VBD	O
acceptable	acceptable	JJ	O
,	,	,	O
while	while	IN	O
C10a	C10a	NNS	O
showed	show	VBD	O
the	the	DT	O
considerable	considerable	JJ	O
cytotoxicity	cytotoxicity	NN	O
.	.	.	O

Compared	compare	VBN	O
with	with	IN	O
15	15	CD	O
,	,	,	O
which	which	WDT	O
exhibited	exhibit	VBD	O
the	the	DT	O
most	most	JJS	O
PTP1B	ptp1b	JJ	O
enzymatic	enzymatic	JJ	O
inhibitory	inhibitory	JJ	O
potency	potency	NN	O
,	,	,	O
compound	compound	NNP	O
25	25	CD	O
has	have	VBZ	O
lower	low	JJR	O
PTP1B	ptp1b	NN	O
inhibition	inhibition	NN	O
26.2âÎ¼M	26.2âÎ¼M	NNP	O
,	,	,	O
but	but	CC	O
it	-PRON-	PRP	O
can	can	MD	O
more	more	RBR	O
significantly	significantly	RB	O
increase	increase	VB	O
insulin	insulin	NN	O
-	-	HYPH	O
stimulated	stimulate	VBN	O
glucose	glucose	NN	O
uptake	uptake	VBD	O
in	in	IN	O
cellular	cellular	JJ	O
assay	assay	NN	O
.	.	.	O

This	this	DT	O
result	result	NN	O
was	be	VBD	O
unsurprising	unsurprise	VBG	O
,	,	,	O
because	because	IN	O
most	most	JJS	O
active	active	JJ	O
site	site	NN	O
-	-	HYPH	O
directed	direct	VBN	O
PTP1B	PTP1B	NNP	O
inhibitors	inhibitor	NNS	O
are	be	VBP	O
phosphotyrosine	phosphotyrosine	JJ	O
mimetics	mimetic	NNS	O
with	with	IN	O
weak	weak	JJ	O
cell	cell	NN	O
permeability	permeability	NN	B
.	.	.	O

We	-PRON-	PRP	O
have	have	VBP	O
previously	previously	RB	O
reported	report	VBN	O
that	that	IN	O
there	there	EX	O
is	be	VBZ	O
a	a	DT	O
trade	trade	NN	O
-	-	HYPH	O
off	off	NN	O
between	between	IN	O
enzymatic	enzymatic	JJ	O
inhibition	inhibition	NN	O
and	and	CC	O
cell	cell	NN	O
permeability	permeability	NN	B
.	.	.	O

We	-PRON-	PRP	O
calculated	calculate	VBD	O
the	the	DT	O
pharmaceutical	pharmaceutical	JJ	O
properties	property	NNS	O
of	of	IN	O
15	15	CD	O
,	,	,	O
25	25	CD	O
and	and	CC	O
C10a	C10a	NNS	O
using	use	VBG	O
the	the	DT	O
Swiss	swiss	JJ	O
ADME	ADME	NNS	O
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Table	table	NN	O
3	3	CD	O
,	,	,	O
the	the	DT	O
MW	mw	NN	O
and	and	CC	O
cLogP	clogp	NN	O
value	value	NN	O
of	of	IN	O
C10a	C10a	NNS	O
are	be	VBP	O
too	too	RB	O
large	large	JJ	O
,	,	,	O
as	as	RB	O
well	well	RB	O
as	as	IN	O
the	the	DT	O
HB	HB	NNP	O
acceptors	acceptor	NNS	O
of	of	IN	O
15	15	CD	O
.	.	.	O

Both	both	DT	O
of	of	IN	O
these	these	DT	O
compounds	compound	NNS	O
could	could	MD	O
not	not	RB	O
fulfil	fulfil	VB	O
Lipinski	Lipinski	NNP	O
Rule	Rule	NNP	B
.	.	.	O

25	25	CD	O
fulfilled	fulfil	VBN	O
Lipinski	Lipinski	NNP	O
Rule	Rule	NNP	O
of	of	IN	O
Five	five	CD	O
and	and	CC	O
has	have	VBZ	O
the	the	DT	O
lowest	low	JJS	O
TPSA	tpsa	NN	O
,	,	,	O
which	which	WDT	O
means	mean	VBZ	O
more	more	RBR	O
acceptable	acceptable	JJ	O
oral	oral	JJ	O
absorption	absorption	NN	O
and	and	CC	O
cell	cell	NN	O
permeability	permeability	NN	O
.	.	.	O

These	these	DT	O
results	result	NNS	O
demonstrated	demonstrate	VBD	O
in	in	IN	O
silico	silico	JJ	O
preferable	preferable	JJ	O
pharmaceutical	pharmaceutical	JJ	O
properties	property	NNS	O
of	of	IN	O
25	25	CD	O
were	be	VBD	O
beneficial	beneficial	JJ	O
for	for	IN	O
its	-PRON-	PRP$	O
cellular	cellular	JJ	O
effect.cLog	effect.clog	NN	O
P	p	NN	O
:	:	:	O
consensus	consensus	NN	O
log	log	NN	O
of	of	IN	O
the	the	DT	O
octanol	octanol	NN	O
/	/	SYM	O
water	water	NN	O
partition	partition	NN	O
coefficient	coefficient	NN	O
;	;	:	O
GI	GI	NNP	O
absorption	absorption	NN	O
:	:	:	O
gastrointestinal	gastrointestinal	JJ	O
absorption	absorption	NN	O
;	;	:	O
MW	mw	NN	O
:	:	:	O
molecular	molecular	JJ	O
weight	weight	NN	O
;	;	:	O
TPSA	tpsa	NN	O
:	:	:	O
topological	topological	JJ	O
polar	polar	JJ	O
surface	surface	NN	O
area	area	NN	O
.	.	.	O

The	the	DT	O
antihyperglycaemic	antihyperglycaemic	JJ	O
effect	effect	NN	O
of	of	IN	O
the	the	DT	O
compounds	compound	NNS	O
15	15	CD	O
,	,	,	O
25	25	CD	O
and	and	CC	O
C10a	C10a	NNS	O
were	be	VBD	O
evaluated	evaluate	VBN	O
on	on	IN	O
non	non	JJ	O
-	-	JJ	O
insulin	insulin	JJ	O
dependent	dependent	JJ	O
diabetes	diabetes	NN	O
mellitus	mellitus	NN	O
mice	mouse	NNS	O
.	.	.	O

Nicotinamide	nicotinamide	NN	O
and	and	CC	O
streptozotocin	streptozotocin	NNS	O
were	be	VBD	O
administrated	administrate	VBN	O
intraperitoneally	intraperitoneally	RB	O
to	to	TO	O
induce	induce	VB	O
hyperglycaemia	hyperglycaemia	NN	O
and	and	CC	O
the	the	DT	O
plasma	plasma	NN	O
glucose	glucose	NN	O
of	of	IN	O
mice	mouse	NNS	O
raised	raise	VBN	O
over	over	IN	O
4.5âmmol	4.5âmmol	CD	O
/	/	SYM	O
L	L	NNP	B
.	.	.	O

Rosiglitazone	rosiglitazone	NN	O
has	have	VBZ	O
not	not	RB	O
shown	show	VBN	O
effect	effect	NN	O
during	during	IN	O
the	the	DT	O
first	first	JJ	O
hour	hour	NN	O
,	,	,	O
but	but	CC	O
it	-PRON-	PRP	O
showed	show	VBD	O
the	the	DT	O
significant	significant	JJ	O
antihyperglycaemic	antihyperglycaemic	JJ	O
effect	effect	NN	O
after	after	IN	O
1âh	1âh	CD	O
Figure	Figure	NNP	O
5	5	CD	O
.	.	.	O

Though	though	IN	O
C10a	C10a	NNS	O
showed	show	VBD	O
the	the	DT	O
antihyperglycaemic	antihyperglycaemic	JJ	O
effect	effect	NN	O
,	,	,	O
some	some	DT	O
mice	mouse	NNS	O
treated	treat	VBN	O
with	with	IN	O
C10a	C10a	NNS	O
appeared	appear	VBD	O
the	the	DT	O
hydroabdomen	hydroabdoman	NNS	O
,	,	,	O
thrombus	thrombus	NN	O
and	and	CC	O
tail	tail	NN	O
necrosis	necrosis	NN	O
,	,	,	O
suggesting	suggest	VBG	O
the	the	DT	O
acute	acute	JJ	O
toxicity	toxicity	NN	O
of	of	IN	O
C10a	C10a	NNS	O
.	.	.	O

Compared	compare	VBN	O
with	with	IN	O
15	15	CD	O
,	,	,	O
25	25	CD	O
showed	show	VBD	O
inÂ	inÂ	NNP	O
vivo	vivo	NNP	O
antihyperglycaemic	antihyperglycaemic	NNP	O
effect	effect	NN	O
,	,	,	O
correlating	correlate	VBG	O
with	with	IN	O
insulin	insulin	NN	O
-	-	HYPH	O
resistant	resistant	JJ	O
cell	cell	NN	O
assay	assay	NN	O
.	.	.	O

The	the	DT	O
antihyperglycaemic	antihyperglycaemic	JJ	O
effect	effect	NN	O
in	in	IN	O
NIDDM	NIDDM	NNP	O
mice	mouse	NNS	O
nâ=â8	nâ=â8	NNP	O
.	.	.	O

Diminution	diminution	NN	O
of	of	IN	O
plasmatic	plasmatic	JJ	O
glucose	glucose	NN	O
concentration	concentration	NN	O
over	over	IN	O
NIDDM	NIDDM	NNP	O
mice	mouse	NNS	O
treated	treat	VBN	O
with	with	IN	O
15	15	CD	O
,	,	,	O
25	25	CD	O
,	,	,	O
C10a	C10a	NNS	O
and	and	CC	O
rosiglitazone	rosiglitazone	NN	O
,	,	,	O
respectively	respectively	RB	O
;	;	:	O
The	the	DT	O
acute	acute	JJ	O
antidiabetic	antidiabetic	JJ	O
effect	effect	NN	O
of	of	IN	O
25	25	CD	O
were	be	VBD	O
observed	observe	VBN	O
with	with	IN	O
respect	respect	NN	O
to	to	IN	O
positive	positive	JJ	O
control	control	NN	O
.	.	.	O

M	M	NNP	O
group	group	NN	O
:	:	:	O
NIDDM	niddm	JJ	O
mice	mouse	NNS	O
were	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
saline	saline	NN	O
alone	alone	JJ	O
.	.	.	O

Y	Y	NNP	O
group	group	NN	O
:	:	:	O
NIDDM	niddm	JJ	O
mice	mouse	NNS	O
were	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
rosiglitazone	rosiglitazone	NN	O
.	.	.	O

In	in	IN	O
this	this	DT	O
article	article	NN	O
,	,	,	O
a	a	DT	O
series	series	NN	O
of	of	IN	O
tricyclic	tricyclic	JJ	O
derivatives	derivative	NNS	O
containing	contain	VBG	O
various	various	JJ	O
hydrophobic	hydrophobic	NN	O
scaffold	scaffold	NN	O
,	,	,	O
linker	linker	NNP	O
and	and	CC	O
aryl	aryl	NNP	O
moiety	moiety	NNP	O
were	be	VBD	O
designed	design	VBN	O
and	and	CC	O
synthesised	synthesise	VBN	O
from	from	IN	O
13-hydroxy-8,11,13-podocarpatriene	13-hydroxy-8,11,13-podocarpatriene	CD	O
,	,	,	O
and	and	CC	O
their	-PRON-	PRP$	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
against	against	IN	O
the	the	DT	O
PTP1B	PTP1B	NNP	O
enzyme	enzyme	NNS	O
was	be	VBD	O
assessed	assess	VBN	O
.	.	.	O

Among	among	IN	O
these	these	DT	O
compounds	compound	NNS	O
,	,	,	O
some	some	DT	O
tricyclic	tricyclic	JJ	O
derivatives	derivative	NNS	O
were	be	VBD	O
described	describe	VBN	O
as	as	IN	O
potent	potent	JJ	O
inhibitors	inhibitor	NNS	O
of	of	IN	O
PTP1B.	PTP1B.	NNP	O
Compound	Compound	NNP	O
25	25	CD	O
showed	show	VBD	O
the	the	DT	O
most	most	JJS	O
effect	effect	NN	O
on	on	IN	O
glucose	glucose	NNP	O
consumption	consumption	NN	O
in	in	IN	O
insulin	insulin	NN	O
-	-	HYPH	O
resistant	resistant	JJ	O
HepG2	HepG2	NNP	O
cells	cell	NNS	O
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
25	25	CD	O
showed	show	VBD	O
the	the	DT	O
most	most	RBS	O
antihyperglycemic	antihyperglycemic	JJ	O
effect	effect	NN	O
in	in	IN	O
NIDDM	niddm	JJ	O
mice	mouse	NNS	O
.	.	.	O

The	the	DT	O
therapeutic	therapeutic	JJ	O
potential	potential	NN	O
of	of	IN	O
PTP1B	PTP1B	NNP	O
inhibition	inhibition	NN	O
,	,	,	O
as	as	RB	O
well	well	RB	O
as	as	IN	O
the	the	DT	O
insulin	insulin	NN	O
sensitising	sensitise	VBG	O
and	and	CC	O
inÂ	inÂ	NNP	O
vivo	vivo	NNP	O
antihyperglycemic	antihyperglycemic	JJ	O
effect	effect	NN	O
of	of	IN	O
these	these	DT	O
compounds	compound	NNS	O
,	,	,	O
made	make	VBD	O
this	this	DT	O
discovery	discovery	NN	O
an	an	DT	O
important	important	JJ	O
opportunity.1H	opportunity.1H	NNP	O
NMR	NMR	NNP	O
spectra	spectra	NNP	O
were	be	VBD	O
recorded	record	VBN	O
on	on	IN	O
a	a	DT	O
Bruker	Bruker	NNP	O
Avance	Avance	NNP	O
400	400	CD	O
spectrometer	spectrometer	NN	O
.	.	.	O

13C	13c	CD	O
NMR	NMR	NNP	O
spectra	spectra	NNP	O
were	be	VBD	O
recorded	record	VBN	O
on	on	IN	O
a	a	DT	O
Bruker	Bruker	NNP	O
DPX	DPX	NNP	O
300	300	CD	O
spectrometer	spectrometer	NN	O
.	.	.	O

TMS	TMS	NNP	O
was	be	VBD	O
the	the	DT	O
internal	internal	JJ	O
standard	standard	NN	O
.	.	.	O

Chemical	chemical	NN	O
shifts	shift	NNS	O
as	as	IN	O
Î	Î	NNP	O
´	´	CD	O
values	value	NNS	O
were	be	VBD	O
recorded	record	VBN	O
in	in	IN	O
ppm	ppm	NN	O
and	and	CC	O
coupling	couple	VBG	O
constants	constant	NNS	O
as	as	IN	O
J	J	NNP	O
values	value	NNS	O
were	be	VBD	O
recorded	record	VBN	O
in	in	IN	O
Hz	Hz	NNP	O
.	.	.	O

HRMS	HRMS	NNP	O
spectra	spectra	NNP	O
were	be	VBD	O
recorded	record	VBN	O
on	on	IN	O
a	a	DT	O
micrOTOF	micrOTOF	NNP	O
-	-	HYPH	O
Q	Q	NNP	O
II	ii	CD	O
10203	10203	CD	O
spectrometer	spectrometer	NN	O
.	.	.	O

TLC	TLC	NNP	O
were	be	VBD	O
performed	perform	VBN	O
on	on	IN	O
the	the	DT	O
HSGF254	HSGF254	NNP	O
silica	silica	NN	O
gel	gel	NN	O
and	and	CC	O
UV	uv	VB	O
detection	detection	NN	O
at	at	IN	O
254ânm	254ânm	CD	O
and	and	CC	O
365ânm	365ânm	CD	O
,	,	,	O
and	and	CC	O
appropriate	appropriate	JJ	O
chromogenic	chromogenic	JJ	O
agents	agent	NNS	O
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
1	1	CD	O
20.00âg	20.00âg	CD	O
,	,	,	O
66.40âmmol	66.40âmmol	CD	O
in	in	IN	O
64âml	64âml	CD	O
of	of	IN	O
HOAc	HOAc	NNS	O
was	be	VBD	O
added	add	VBN	O
to	to	IN	O
33	33	CD	O
%	%	NN	O
HBr	HBr	NNS	O
/	/	SYM	O
HOAc	HOAc	NNS	O
64âml	64âml	CD	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
rt	rt	NNP	O
for	for	IN	O
6âh	6âh	CD	O
,	,	,	O
and	and	CC	O
then	then	RB	O
was	be	VBD	O
filtered	filter	VBN	O
and	and	CC	O
the	the	DT	O
filter	filter	NN	O
cake	cake	NN	O
was	be	VBD	O
washed	wash	VBN	O
with	with	IN	O
HOAc	HOAc	NNS	O
,	,	,	O
dried	dry	VBN	O
in	in	IN	O
vacuum	vacuum	NN	O
overnight	overnight	RB	O
to	to	TO	O
give	give	VB	O
corresponding	correspond	VBG	O
crude	crude	JJ	O
dibromo	dibromo	JJ	O
derivative	derivative	NN	O
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
the	the	DT	O
crude	crude	JJ	O
8,15-dibromo	8,15-dibromo	NNP	O
derivative	derivative	NN	O
was	be	VBD	O
added	add	VBN	O
LiOH	LiOH	NNP	O
2.64âg	2.64âg	CD	O
,	,	,	O
64.72âmmol	64.72âmmol	CD	O
in	in	IN	O
200âml	200âml	CD	O
of	of	IN	O
DMF	DMF	NNP	O
,	,	,	O
and	and	CC	O
the	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
80âÂ	80âÂ	NNP	O
°	°	NNP	O
C	C	NNP	O
for	for	IN	O
7âh	7âh	CD	O
.	.	.	O

Solvent	Solvent	NNP	O
was	be	VBD	O
removed	remove	VBN	O
under	under	IN	O
reduced	reduce	VBN	O
pressure	pressure	NN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
pH	pH	NNP	O
was	be	VBD	O
adjusted	adjust	VBN	O
to	to	IN	O
3	3	CD	O
with	with	IN	O
HCl	HCl	NNS	O
and	and	CC	O
concentrated	concentrate	VBD	O
to	to	TO	O
give	give	VB	O
a	a	DT	O
brown	brown	JJ	O
oil	oil	NN	O
2	2	CD	O
without	without	IN	O
further	further	JJ	O
purification	purification	NN	O
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
1	1	CD	O
equiv	equiv	NN	O
.	.	.	O

diene	diene	NNP	O
in	in	IN	O
10âml	10âml	NNP	O
/	/	SYM	O
mmol	mmol	NN	O
of	of	IN	O
dry	dry	JJ	O
THF	THF	NNP	O
was	be	VBD	O
added	add	VBN	O
4	4	CD	O
equiv	equiv	NN	O
.	.	.	O

SeO2	SeO2	NNS	O
,	,	,	O
and	and	CC	O
the	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
0âÂ	0ââ	CD	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
5âh	5âh	CD	O
under	under	IN	O
an	an	DT	O
atmosphere	atmosphere	NN	O
of	of	IN	O
Ar	Ar	NNP	O
.	.	.	O

The	the	DT	O
solid	solid	JJ	O
was	be	VBD	O
removed	remove	VBN	O
by	by	IN	O
filtration	filtration	NN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
filtrate	filtrate	JJ	O
was	be	VBD	O
extracted	extract	VBN	O
with	with	IN	O
EtOAc	EtOAc	NNS	O
.	.	.	O

Solvent	Solvent	NNP	O
was	be	VBD	O
removed	remove	VBN	O
under	under	IN	O
reduced	reduce	VBN	O
pressure	pressure	NN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
resulting	result	VBG	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
flash	flash	NN	O
column	column	NN	O
chromatography	chromatography	NN	O
to	to	TO	O
give	give	VB	O
product	product	NN	O
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
1	1	CD	O
equiv	equiv	NN	O
.	.	.	O

abieta-18-oic	abieta-18-oic	JJ	O
acid	acid	NN	O
in	in	IN	O
acetone	acetone	NN	O
was	be	VBD	O
added	add	VBN	O
3	3	CD	O
equiv	equiv	NN	O
.	.	.	O

K2CO3	K2CO3	NNP	O
,	,	,	O
and	and	CC	O
the	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
for	for	IN	O
15âmin	15âmin	CD	O
.	.	.	O

The	the	DT	O
solution	solution	NN	O
was	be	VBD	O
dropwise	dropwise	NN	O
added	add	VBN	O
2	2	CD	O
equiv	equiv	NN	O
.	.	.	O

EtI	EtI	NNP	O
or	or	CC	O
BnBr	BnBr	NNP	O
for	for	IN	O
4âb	4âb	CD	O
and	and	CC	O
the	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
60âÂ	60âÂ	NNP	O
°	°	NNP	O
C	C	NNP	O
for	for	IN	O
3âh	3âh	CD	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
extracted	extract	VBN	O
with	with	IN	O
EtOAc	EtOAc	NNS	O
.	.	.	O

Solvent	Solvent	NNP	O
was	be	VBD	O
removed	remove	VBN	O
under	under	IN	O
reduced	reduce	VBN	O
pressure	pressure	NN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
resulting	result	VBG	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
flash	flash	NN	O
column	column	NN	O
chromatography	chromatography	NN	O
to	to	TO	O
give	give	VB	O
product	product	NN	O
.	.	.	O

To	to	IN	O
a	a	DT	O
suspension	suspension	NN	O
of	of	IN	O
4	4	CD	O
equiv	equiv	NN	O
.	.	.	O

LiAlH4	LiAlH4	NNP	O
in	in	IN	O
THF	THF	NNP	O
was	be	VBD	O
added	add	VBN	O
1	1	CD	O
equiv	equiv	IN	O
.	.	.	O

ester	ester	NN	O
in	in	IN	O
10âml	10âml	NNP	O
/	/	SYM	O
mmol	mmol	NN	O
of	of	IN	O
THF	THF	NNP	O
at	at	IN	O
0âÂ	0ââ	CD	O
°	°	NNS	O
C	C	NNP	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
rt	rt	NNP	O
for	for	IN	O
3âh	3âh	CD	O
,	,	,	O
and	and	CC	O
then	then	RB	O
was	be	VBD	O
quenched	quench	VBN	O
by	by	IN	O
addition	addition	NN	O
of	of	IN	O
aq	aq	NNP	O
.	.	.	O

NaOH	NaOH	NNP	O
.	.	.	O

The	the	DT	O
resulting	result	VBG	O
solid	solid	JJ	O
was	be	VBD	O
filtered	filter	VBN	O
off	off	RP	O
.	.	.	O

Solvent	solvent	NN	O
of	of	IN	O
the	the	DT	O
filtrate	filtrate	NN	O
was	be	VBD	O
removed	remove	VBN	O
under	under	IN	O
reduced	reduce	VBN	O
pressure	pressure	NN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
resulting	result	VBG	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
flash	flash	NN	O
column	column	NN	O
chromatography	chromatography	NN	O
to	to	TO	O
give	give	VB	O
product	product	NN	O
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
1	1	CD	O
equiv	equiv	NN	O
.	.	.	O

ester	ester	NN	O
5	5	CD	O
in	in	IN	O
5âml	5âml	CD	O
/	/	SYM	O
mmol	mmol	NN	O
AcOH	AcOH	NNP	O
was	be	VBD	O
added	add	VBN	O
3	3	CD	O
equiv	equiv	NN	O
.	.	.	O

t	t	LS	O
-	-	:	O
BuOOH	BuOOH	NNP	O
followed	follow	VBN	O
by	by	IN	O
addition	addition	NN	O
of	of	IN	O
0.1	0.1	CD	O
equiv	equiv	JJ	O
.	.	.	O

H2SO4	H2SO4	NNP	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
50âÂ	50âÂ	NNP	O
°	°	NNP	O
C	C	NNP	O
for	for	IN	O
1âh	1âh	CD	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
diluted	dilute	VBN	O
with	with	IN	O
water	water	NN	O
and	and	CC	O
the	the	DT	O
aqueous	aqueous	JJ	O
phase	phase	NN	O
was	be	VBD	O
extracted	extract	VBN	O
with	with	IN	O
DCM	DCM	NNP	O
.	.	.	O

The	the	DT	O
organic	organic	JJ	O
phase	phase	NN	O
was	be	VBD	O
washed	wash	VBN	O
with	with	IN	O
Na2CO3	Na2CO3	NNP	O
,	,	,	O
water	water	NN	O
and	and	CC	O
dried	dry	VBN	O
.	.	.	O

Solvent	Solvent	NNP	O
was	be	VBD	O
removed	remove	VBN	O
under	under	IN	O
reduced	reduce	VBN	O
pressure	pressure	NN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
resulting	result	VBG	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
flash	flash	NN	O
column	column	NN	O
chromatography	chromatography	NN	O
to	to	TO	O
furnish	furnish	VB	O
the	the	DT	O
product	product	NN	O
.	.	.	O

The	the	DT	O
solution	solution	NN	O
of	of	IN	O
1	1	CD	O
equiv	equiv	NN	O
.	.	.	O

alcohol	alcohol	NNP	O
and	and	CC	O
5	5	CD	O
equiv	equiv	JJ	O
.	.	.	O

tolylsulfonyl	tolylsulfonyl	NN	O
chloride	chloride	NN	O
in	in	IN	O
3âml	3âml	CD	O
/	/	SYM	O
mmol	mmol	NN	O
of	of	IN	O
pyridine	pyridine	NNP	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
rt	rt	NNP	O
for	for	IN	O
6âh	6âh	CD	O
.	.	.	O

After	after	IN	O
removal	removal	NN	O
of	of	IN	O
solvent	solvent	NN	O
by	by	IN	O
evaporation	evaporation	NN	O
,	,	,	O
the	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
dissolved	dissolve	VBN	O
in	in	IN	O
DCM	DCM	NNP	O
,	,	,	O
followed	follow	VBN	O
by	by	IN	O
washed	wash	VBN	O
and	and	CC	O
dried	dry	VBD	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
then	then	RB	O
concentrated	concentrate	VBN	O
and	and	CC	O
subjected	subject	VBN	O
to	to	IN	O
flash	flash	NN	O
column	column	NN	O
chromatography	chromatography	NN	O
to	to	TO	O
furnish	furnish	VB	O
the	the	DT	O
product	product	NN	O
.	.	.	O

The	the	DT	O
solution	solution	NN	O
of	of	IN	O
1	1	CD	O
equiv	equiv	NN	O
.	.	.	O

p	p	NN	O
-	-	HYPH	O
toluenesulfonate	toluenesulfonate	NN	O
,	,	,	O
10	10	CD	O
equiv	equiv	NN	O
.	.	.	O

zinc	zinc	NNP	O
and	and	CC	O
5	5	CD	O
equiv	equiv	NN	O
.	.	.	O

sodium	sodium	NN	O
iodide	iodide	NNP	O
in	in	IN	O
10âml	10âml	NNP	O
/	/	SYM	O
mmol	mmol	NN	O
of	of	IN	O
HMPA	HMPA	NNP	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
105âÂ	105ââ	CD	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
7âh	7âh	CD	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
dissolved	dissolve	VBN	O
in	in	IN	O
water	water	NN	O
and	and	CC	O
the	the	DT	O
aqueous	aqueous	JJ	O
layer	layer	NN	O
was	be	VBD	O
extracted	extract	VBN	O
with	with	IN	O
EtOAc	EtOAc	NNS	O
.	.	.	O

The	the	DT	O
combined	combined	JJ	O
organic	organic	JJ	O
layers	layer	NNS	O
were	be	VBD	O
washed	wash	VBN	O
with	with	IN	O
brine	brine	NN	O
and	and	CC	O
dried	dry	VBD	O
.	.	.	O

Solvent	Solvent	NNP	O
was	be	VBD	O
removed	remove	VBN	O
under	under	IN	O
reduced	reduce	VBN	O
pressure	pressure	NN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
resulting	result	VBG	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
flash	flash	NN	O
column	column	NN	O
chromatography	chromatography	NN	O
to	to	TO	O
furnish	furnish	VB	O
the	the	DT	O
product	product	NN	O
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
1	1	CD	O
equiv	equiv	NN	O
.	.	.	O

carboxylic	carboxylic	JJ	O
acid	acid	NN	O
in	in	IN	O
1.5	1.5	CD	O
equiv	equiv	NN	O
.	.	.	O

diol	diol	NNP	O
was	be	VBD	O
added	add	VBN	O
to	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
1.5	1.5	CD	O
equiv	equiv	NN	O
.	.	.	O

DCC	DCC	NNP	O
and	and	CC	O
0.05	0.05	CD	O
equiv	equiv	NN	O
.	.	.	O

DMAP	DMAP	NNS	O
in	in	IN	O
5âml	5âml	CD	O
/	/	SYM	O
mmol	mmol	NN	O
of	of	IN	O
acetonitrile	acetonitrile	NN	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
0âÂ	0ââ	CD	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
1âh	1âh	CD	O
,	,	,	O
then	then	RB	O
transferred	transfer	VBN	O
to	to	IN	O
rt	rt	NNP	O
and	and	CC	O
stirred	stir	VBN	O
for	for	IN	O
5âh	5âh	CD	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
extracted	extract	VBN	O
with	with	IN	O
EtOAc	EtOAc	NNS	O
.	.	.	O

The	the	DT	O
combined	combined	JJ	O
organic	organic	JJ	O
layers	layer	NNS	O
were	be	VBD	O
washed	wash	VBN	O
with	with	IN	O
brine	brine	NN	O
and	and	CC	O
dried	dry	VBD	O
.	.	.	O

Solvent	Solvent	NNP	O
was	be	VBD	O
removed	remove	VBN	O
under	under	IN	O
reduced	reduce	VBN	O
pressure	pressure	NN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
resulting	result	VBG	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
flash	flash	NN	O
column	column	NN	O
chromatography	chromatography	NN	O
to	to	TO	O
furnish	furnish	VB	O
the	the	DT	O
product	product	NN	O
.	.	.	O

A	a	DT	O
solution	solution	NN	O
of	of	IN	O
3	3	CD	O
equiv	equiv	NN	O
.	.	.	O

ester	ester	NN	O
in	in	IN	O
2âml	2âml	CD	O
/	/	SYM	O
mmol	mmol	NN	O
of	of	IN	O
DMF	DMF	NNP	O
was	be	VBD	O
added	add	VBN	O
to	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
1	1	CD	O
equiv	equiv	NN	O
.	.	.	O

6b	6b	NNS	O
and	and	CC	O
5	5	CD	O
equiv	equiv	NN	O
.	.	.	O

K2CO3	K2CO3	NNP	O
in	in	IN	O
2âml	2âml	CD	O
/	/	SYM	O
mmol	mmol	NN	O
of	of	IN	O
DMF	DMF	NNP	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
80âÂ	80âÂ	NNP	O
°	°	NNP	O
C	C	NNP	O
for	for	IN	O
5âh	5âh	CD	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
extracted	extract	VBN	O
with	with	IN	O
EtOAc	EtOAc	NNS	O
.	.	.	O

The	the	DT	O
combined	combined	JJ	O
organic	organic	JJ	O
layers	layer	NNS	O
were	be	VBD	O
washed	wash	VBN	O
with	with	IN	O
brine	brine	NN	O
and	and	CC	O
dried	dry	VBD	O
.	.	.	O

Solvent	Solvent	NNP	O
was	be	VBD	O
removed	remove	VBN	O
under	under	IN	O
reduced	reduce	VBN	O
pressure	pressure	NN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
resulting	result	VBG	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
flash	flash	NN	O
column	column	NN	O
chromatography	chromatography	NN	O
to	to	TO	O
furnish	furnish	VB	O
the	the	DT	O
product	product	NN	O
.	.	.	O

Pd	pd	UH	O
/	/	SYM	O
C	C	NNP	O
10	10	CD	O
%	%	NN	O
,	,	,	O
1âmg	1âmg	CD	O
/	/	SYM	O
mg	mg	NNP	O
was	be	VBD	O
added	add	VBN	O
to	to	IN	O
the	the	DT	O
solution	solution	NN	O
of	of	IN	O
1	1	CD	O
equiv	equiv	NN	O
.	.	.	O

benzyl	benzyl	NNP	O
ester	ester	NN	O
in	in	IN	O
10âml	10âml	NNP	O
/	/	SYM	O
mmol	mmol	NN	O
of	of	IN	O
methanol	methanol	NN	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
hydrogenolised	hydrogenolise	VBN	O
under	under	IN	O
1âMPa	1âmpa	CD	O
at	at	IN	O
rt	rt	NNP	O
for	for	IN	O
12âh	12âh	CD	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
filtered	filter	VBN	O
.	.	.	O

Solvent	solvent	NN	O
of	of	IN	O
the	the	DT	O
filtrate	filtrate	NN	O
was	be	VBD	O
removed	remove	VBN	O
under	under	IN	O
reduced	reduce	VBN	O
pressure	pressure	NN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
resulting	result	VBG	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
flash	flash	NN	O
column	column	NN	O
chromatography	chromatography	NN	O
to	to	TO	O
furnish	furnish	VB	O
the	the	DT	O
product	product	NN	O
.	.	.	O

The	the	DT	O
inhibitory	inhibitory	NN	O
assay	assay	NN	O
was	be	VBD	O
performed	perform	VBN	O
using	use	VBG	O
human	human	JJ	O
PTP1B	PTP1B	NNS	O
and	and	CC	O
p	p	NN	O
-	-	HYPH	O
nitrophenylphosphate	nitrophenylphosphate	NN	O
as	as	IN	O
substrate	substrate	NN	O
by	by	IN	O
UV	uv	NN	O
absorption	absorption	NN	O
.	.	.	O

400ânmol	400ânmol	CD	O
pNPP	pNPP	NNS	O
were	be	VBD	O
dissolved	dissolve	VBN	O
in	in	IN	O
H2O	h2o	NN	O
and	and	CC	O
48âÎ¼L	48âî¼l	CD	O
of	of	IN	O
the	the	DT	O
solution	solution	NN	O
was	be	VBD	O
added	add	VBN	O
to	to	IN	O
a	a	DT	O
100âÎ¼L	100âî¼l	CD	O
reaction	reaction	NN	O
.	.	.	O

The	the	DT	O
indicated	indicate	VBN	O
amount	amount	NN	O
of	of	IN	O
synthetic	synthetic	JJ	O
compounds	compound	NNS	O
was	be	VBD	O
diluted	dilute	VBN	O
in	in	IN	O
DMSO	DMSO	NNP	O
at	at	IN	O
a	a	DT	O
concentration	concentration	NN	O
of	of	IN	O
5âmM.	5âmm.	CD	O
The	the	DT	O
PTP1B	PTP1B	NNP	O
was	be	VBD	O
diluted	dilute	VBN	O
in	in	IN	O
pH	pH	NNP	O
7.2	7.2	CD	O
buffer	buffer	NN	O
contained	contain	VBD	O
50âmM	50âmm	CD	O
HEPES	HEPES	NNP	O
,	,	,	O
3âmM	3âmm	CD	O
dithiothreitol	dithiothreitol	NNP	O
,	,	,	O
2âmM	2âmm	CD	O
EDTA	EDTA	NNP	O
and	and	CC	O
100âmM	100âmm	CD	O
NaCl	NaCl	NNP	O
.	.	.	O

About	about	RB	O
50âÎ¼L	50âî¼l	CD	O
PTP1B	PTP1B	NNP	O
dilution	dilution	NN	O
was	be	VBD	O
added	add	VBN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
mixture	mixture	NN	O
incubated	incubate	VBD	O
at	at	IN	O
37âÂ	37ââ	CD	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
30âmin	30âmin	NNP	O
.	.	.	O

1N	1N	NNP	O
NaOH	NaOH	NNP	O
was	be	VBD	O
added	add	VBN	O
to	to	TO	O
terminate	terminate	VB	O
the	the	DT	O
reaction	reaction	NN	O
.	.	.	O

UVâVis	UVâVis	NNP	O
absorption	absorption	NN	O
was	be	VBD	O
detected	detect	VBN	O
at	at	IN	O
410ânm	410ânm	CD	O
using	use	VBG	O
a	a	DT	O
Tecan	Tecan	NNP	O
Infinite	Infinite	NNP	O
M1000	M1000	NNP	O
plate	plate	NN	O
reader	reader	NN	O
.	.	.	O

HepG2	hepg2	NN	O
cells	cell	NNS	O
were	be	VBD	O
grown	grow	VBN	O
in	in	IN	O
DMEM	DMEM	NNP	O
with	with	IN	O
10	10	CD	O
%	%	NN	O
foetal	foetal	JJ	O
bovine	bovine	NN	O
serum	serum	NN	O
,	,	,	O
100âmg	100âmg	CD	O
/	/	SYM	O
mL	mL	NNP	O
of	of	IN	O
streptomycin	streptomycin	NNP	O
,	,	,	O
and	and	CC	O
100âU	100âU	NNP	O
/	/	SYM	O
mL	mL	NNP	O
of	of	IN	O
penicillin	penicillin	NNP	O
,	,	,	O
in	in	IN	O
a	a	DT	O
humidified	humidified	JJ	O
atmosphere	atmosphere	NN	O
of	of	IN	O
5	5	CD	O
%	%	NN	O
CO2	CO2	NNP	O
at	at	IN	O
37âÂ	37ââ	CD	O
°	°	,	O
C	C	NNP	O
.	.	.	O

HepG2	hepg2	NN	O
cells	cell	NNS	O
were	be	VBD	O
cultured	culture	VBN	O
in	in	IN	O
96-well	96-well	CD	O
tuft	tuft	NN	O
plates	plate	NNS	O
.	.	.	O

After	after	IN	O
overnight	overnight	JJ	O
incubation	incubation	NN	O
,	,	,	O
the	the	DT	O
cells	cell	NNS	O
were	be	VBD	O
serum	serum	NN	O
starved	starve	VBN	O
for	for	IN	O
12âh	12âh	CD	O
.	.	.	O

Then	then	RB	O
,	,	,	O
the	the	DT	O
cells	cell	NNS	O
were	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
insulin	insulin	NN	O
6âÃâ10â6â5âÃâ10â5âmmol	6âãâ10â6â5âãâ10â5âmmol	NN	O
/	/	SYM	O
L	L	NNP	O
for	for	IN	O
0â60âh	0â60âh	CD	O
to	to	TO	O
induce	induce	VB	O
insulin	insulin	NN	O
resistance	resistance	NN	O
.	.	.	O

HepG2	hepg2	NN	O
cells	cell	NNS	O
were	be	VBD	O
then	then	RB	O
cultured	cultured	JJ	O
for	for	IN	O
another	another	DT	O
24âh	24âh	CD	O
in	in	IN	O
the	the	DT	O
compound	compound	NN	O
40âÎ¼M	40âî¼m	NN	O
or	or	CC	O
rosiglitazone	rosiglitazone	NN	O
10âÎ¼M	10âî¼m	CD	O
,	,	,	O
available	available	JJ	O
from	from	IN	O
Bied	Bied	NNP	O
Pharmaceutical	Pharmaceutical	NNP	O
Technology	Technology	NNP	O
Co.	Co.	NNP	O
,	,	,	O
Ltd.	Ltd.	NNP	O
,	,	,	O
Shanghai	Shanghai	NNP	O
,	,	,	O
China	China	NNP	O
containing	contain	VBG	O
DMEM	DMEM	NNS	O
.	.	.	O

After	after	IN	O
cultivation	cultivation	NN	O
,	,	,	O
the	the	DT	O
glucose	glucose	NN	O
content	content	NN	O
was	be	VBD	O
determined	determine	VBN	O
by	by	IN	O
the	the	DT	O
glucose	glucose	NN	O
oxidase	oxidase	NN	O
method	method	NN	O
.	.	.	O

The	the	DT	O
sample	sample	NN	O
and	and	CC	O
the	the	DT	O
kit	kit	NN	O
working	working	NN	O
solution	solution	NN	O
were	be	VBD	O
thoroughly	thoroughly	RB	O
mixed	mix	VBN	O
at	at	IN	O
a	a	DT	O
ratio	ratio	NN	O
of	of	IN	O
1:100	1:100	CD	O
,	,	,	O
and	and	CC	O
placed	place	VBN	O
in	in	IN	O
a	a	DT	O
37âÂ	37âÂ	NNP	O
°	°	,	O
C	c	NN	O
water	water	NN	O
bath	bath	NN	O
for	for	IN	O
15âmin	15âmin	CD	O
.	.	.	O

The	the	DT	O
absorbance	absorbance	NN	O
was	be	VBD	O
measured	measure	VBN	O
at	at	IN	O
506ânm	506ânm	CD	O
using	use	VBG	O
a	a	DT	O
microplate	microplate	NN	O
reader	reader	NN	O
.	.	.	O

The	the	DT	O
residual	residual	JJ	O
glucose	glucose	NN	O
concentration	concentration	NN	O
is	be	VBZ	O
expressed	express	VBN	O
as	as	IN	O
AX	AX	NNP	O
/	/	SYM	O
A0	A0	NNP	O
Ã	Ã	NNP	O
5.55âmmol	5.55âmmol	NNP	O
/	/	SYM	O
L	L	NNP	O
.	.	.	O

During	during	IN	O
the	the	DT	O
experiment	experiment	NN	O
,	,	,	O
the	the	DT	O
male	male	JJ	O
Kunming	Kunming	NNP	O
mice	mouse	NNS	O
with	with	IN	O
25â30âg	25â30âg	CD	O
body	body	NN	O
weight	weight	NN	O
were	be	VBD	O
fasted	fast	VBN	O
but	but	CC	O
received	receive	VBD	O
water	water	NN	O
prior	prior	RB	O
to	to	IN	O
induction	induction	NN	O
of	of	IN	O
diabetes	diabete	NNS	O
.	.	.	O

110âmg	110âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
of	of	IN	O
nicotinamide	nicotinamide	NN	O
and	and	CC	O
65âmg	65âmg	NNS	O
/	/	SYM	O
kg	kg	NNS	O
of	of	IN	O
streptozotocin	streptozotocin	NNS	O
were	be	VBD	O
dissolved	dissolve	VBN	O
in	in	IN	O
pH	pH	NNP	O
4.5	4.5	CD	O
citrate	citrate	NN	O
buffer	buffer	NN	O
and	and	CC	O
intraperitoneally	intraperitoneally	RB	O
administrated	administrate	VBD	O
to	to	TO	O
induce	induce	VB	O
NIDDM	NIDDM	NNP	O
mice	mouse	NNS	O
model	model	NN	O
.	.	.	O

The	the	DT	O
mice	mouse	NNS	O
were	be	VBD	O
intraperitoneally	intraperitoneally	RB	O
administered	administer	VBN	O
with	with	IN	O
a	a	DT	O
compound	compound	NN	O
or	or	CC	O
rosiglitazone	rosiglitazone	NN	O
100âmg	100âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
dissolved	dissolve	VBN	O
in	in	IN	O
saline	saline	NN	O
containing	contain	VBG	O
1	1	CD	O
%	%	NN	O
DMSO	DMSO	NNS	O
and	and	CC	O
10	10	CD	O
%	%	NN	O
Tween	Tween	NNP	O
80	80	CD	O
.	.	.	O

Hyperglycaemia	Hyperglycaemia	NNP	O
was	be	VBD	O
confirmed	confirm	VBN	O
by	by	IN	O
a	a	DT	O
plasma	plasma	NN	O
glucose	glucose	NN	O
increase	increase	NN	O
of	of	IN	O
more	more	JJR	O
than	than	IN	O
4.5âmmol	4.5âmmol	CD	O
/	/	SYM	O
L	l	NN	O
measured	measure	VBN	O
by	by	IN	O
a	a	DT	O
blood	blood	NN	O
glucose	glucose	NN	O
metre	metre	NN	O
.	.	.	O

Glucose	Glucose	NNP	O
concentrations	concentration	NNS	O
from	from	IN	O
the	the	DT	O
tail	tail	NN	O
of	of	IN	O
the	the	DT	O
mice	mouse	NNS	O
were	be	VBD	O
measured	measure	VBN	O
at	at	IN	O
0	0	CD	O
,	,	,	O
0.5	0.5	CD	O
,	,	,	O
1	1	CD	O
,	,	,	O
2	2	CD	O
,	,	,	O
3	3	CD	O
and	and	CC	O
4âh	4âh	CD	O
by	by	IN	O
the	the	DT	O
blood	blood	NN	O
glucose	glucose	NN	O
metre	metre	NNP	O
.	.	.	O

Calculate	calculate	VB	O
the	the	DT	O
percentage	percentage	NN	O
of	of	IN	O
blood	blood	NN	O
glucose	glucose	NN	O
by	by	IN	O
using	use	VBG	O
the	the	DT	O
following	follow	VBG	O
formula	formula	NN	O
:	:	:	O
variation	variation	NN	O
of	of	IN	O
glycaemia%	glycaemia%	NNP	O
=	=	NFP	O
AX	AX	NNP	O
â	â	NNP	O
A0)/A0	a0)/a0	NN	O
Ã	ã	CC	O
100	100	CD	O
%	%	NN	O
.	.	.	O

